121 related articles for article (PubMed ID: 2128967)
1. Use of plasma with high levels of ionised calcium in the production of model scale coagulation factor concentrates.
Farrugia A; Douglas S; James J; Whyte G; Herrington R
Thromb Haemost; 1990 Nov; 64(3):374-8. PubMed ID: 2128967
[TBL] [Abstract][Full Text] [Related]
2. The stability of factor VIII in heparinized plasma.
Krachmalnicoff A; Thomas DP
Thromb Haemost; 1983 Jun; 49(3):224-7. PubMed ID: 6410534
[TBL] [Abstract][Full Text] [Related]
3. Whole blood collection using metered anticoagulation for production of Factor VIII and Factor IX.
Penny A; Pinner M; Townley A; Mosley P; Smith J; Lane R; Munford C; Robinson A
Prog Clin Biol Res; 1990; 337():487-9. PubMed ID: 2112756
[No Abstract] [Full Text] [Related]
4. Quality of plasma for fractionation--does it matter?
Smith JK
Transfus Sci; 1994 Dec; 15(4):343-50. PubMed ID: 10155552
[TBL] [Abstract][Full Text] [Related]
5. A simple plasma anticoagulant-exchange method to increase the recovery of factor VIII in therapeutic concentrates.
Cumming AM; Wensley RT; Winkelman L; Lane RS
Vox Sang; 1990; 58(4):264-9. PubMed ID: 2119086
[TBL] [Abstract][Full Text] [Related]
6. Citrate anticoagulation and the dynamics of thrombin generation.
Mann KG; Whelihan MF; Butenas S; Orfeo T
J Thromb Haemost; 2007 Oct; 5(10):2055-61. PubMed ID: 17883701
[TBL] [Abstract][Full Text] [Related]
7. [Possibilities to elevate the factor VIII yield].
Uteg KH; Tausendfreund K
Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(1):153-69. PubMed ID: 2439416
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
Prowse CV; Williams AE
Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
[TBL] [Abstract][Full Text] [Related]
9. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
Prowse CV; Boffa MC; Guthrie C; Pepper DS
Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
[TBL] [Abstract][Full Text] [Related]
10. Increased yield of F VIII from pooled plasma vs. single-donor plasma in the production of cryoprecipitates.
Rácz Z; Thék M; Jánossy A; Pintér J; Baróti C
Arch Med Res; 1997; 28(2):179-82. PubMed ID: 9204605
[TBL] [Abstract][Full Text] [Related]
11. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
[TBL] [Abstract][Full Text] [Related]
12. [Thrombogenicity of prothrombin complex concentrates].
Dornheim G; Klöcking HP; Wulkow R; Storch H; Töpfer G
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):571-9. PubMed ID: 1714862
[TBL] [Abstract][Full Text] [Related]
13. [Changes in ionized calcium and citrate levels in dogs during mechanical autotransfusion with heparin, ACD and CPD].
Klaue P; Maier H; Feldmann K; Homann B
Chir Forum Exp Klin Forsch; 1979; ():255-9. PubMed ID: 456136
[TBL] [Abstract][Full Text] [Related]
14. Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.
Farrugia A
Australas Biotechnol; 1993; 3(1):16-20. PubMed ID: 7763537
[TBL] [Abstract][Full Text] [Related]
15. A therapeutic concentrate of coagulation factors II, IX and X from citrated, factor VIII-depleted plasma.
Middleton SM; Bennett IH; Smith JK
Vox Sang; 1973 May; 24(5):441-56. PubMed ID: 4691239
[No Abstract] [Full Text] [Related]
16. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
Johnson AJ; Mathews RW; Fulton AJ
Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
[TBL] [Abstract][Full Text] [Related]
17. Calcium-specific immunoassays for factor IX: reduced levels of antigen in patients with vitamin K disorders.
Bray GL; Weinmann AF; Thompson AR
J Lab Clin Med; 1986 Mar; 107(3):269-78. PubMed ID: 3485164
[TBL] [Abstract][Full Text] [Related]
18. Effects of plasma collection systems and processing parameters on the quality of factor IX concentrate.
Farrugia A; Spiers D; Young I; Oates A; Herrington R; Damianos F
Vox Sang; 1989; 57(1):4-9. PubMed ID: 2800464
[TBL] [Abstract][Full Text] [Related]
19. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
20. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.
Makris M; Greaves M; Phillips WS; Kitchen S; Rosendaal FR; Preston EF
Thromb Haemost; 1997 Mar; 77(3):477-80. PubMed ID: 9065997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
